Asensus Surgical (NYSE:ASXC) announced today that a private Russian healthcare institution began a program with its Senhance system.
Research Triangle Park, North Carolina-based Asensus said in a news release that Rostov, Russia-based Railway Clinical Hospital RZD Medicine of Rostov-on-Don (RZD Medicine) purchased a Senhance surgical robotic system and initiated a robotic surgery program with the platform.
“We are excited to bring Senhance to such a prestigious, forward-thinking institution. RZD Medicine is home to a high volume, multidisciplinary general surgery department that can leverage Senhance across a wide variety of procedures,” Asensus Surgical President & CEO Anthony Fernando said in the release. “We are excited to see hospitals in Russia starting to adopt Senhance, and we look forward to partnering with others in the region in the future.”
Senhance, which Asensus touts as a first-of-its-kind digital laparoscopic platform for leveraging augmented intelligence to offer positive surgical outcomes through machine learning with haptic feedback, eye-tracking camera control and 3D visualization.
“Ultimately, our goal is to get patients back to their daily life as quickly as possible,” RZD Medicine Head of General Surgery Dr. Aleksandr Khitharyan said. “Senhance’s broad applicability across a variety of surgical procedures, and its ability to deliver high quality, reproducible outcomes while at the same time reducing the invasiveness of procedures will allow us to accomplish our goal.”